Omeros Corporation Insider Buys: Demopulos Acquires 15,000 Shares
Peter Demopulos purchased 15,000 shares of Omeros Corporation on June 18, 2026.
Key Points
- Peter Demopulos bought 15,000 shares of Omeros Corporation on June 18, 2026, with the stock trading near $10.28.
- Omeros Corporation, a biotech firm, has a market cap of about $744 million and a P/E ratio of 9.02.
- Analysts maintain a 'buy' rating on Omeros with a mean target price of $40.0.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Peter Demopulos added 15,000 shares to his holdings in Omeros Corporation (NASDAQ: OMER). This insider purchase comes as the stock traded near $10.28 on Monday.
Insider Buying and Selling at Omeros Corporation
Several insiders, including Peter Demopulos, bought 15,000 shares each of Omeros Corporation on June 18, 2026. These transactions were not part of a pre-arranged trading plan. Other insiders making similar purchases include Leroy Hood MD PhD, Diana Perkinson, Rajiv Shah, Thomas Bumol, and Arnold Hanish.
Other Institutional Activity in Omeros Corporation
BlackRock, Inc. increased its holdings by 247,188 shares, reaching a total of 5,309,626 shares valued at about $56.1 million. Ingalls & Snyder LLC also added 110,724 shares, bringing its total to 3,559,423 shares worth approximately $37.6 million. Vanguard Capital Management LLC opened a new position with 2,983,259 shares, valued at $31.5 million. UBS Group AG grew its stake by 117,749 shares, now holding 2,340,731 shares valued at $24.7 million. State Street Corp boosted its holdings by 346,049 shares, totaling 1,919,575 shares worth $20.3 million.
Omeros Corporation Stock Down 44.5%
Shares of NASDAQ:OMER traded near $10.28 on Monday. Omeros Corporation has a market capitalization of approximately $744 million. The company holds a P/E ratio of 9.02 and a beta of 2.53. The stock's 52-week range is between $2.95 and $17.65, with a 50-day moving average of $12.22 and a 200-day moving average of $10.11. Omeros maintains a current ratio of 3.03 and a quick ratio of 2.48.
$OMER stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts from firms like D. Boral Capital and HC Wainwright & Co. have maintained their 'buy' ratings on Omeros Corporation. D. Boral Capital kept its price target at $36.0 as of April 21, 2026. HC Wainwright & Co. set a target of $40.0 on January 8, 2026. The consensus among analysts is a 'buy' recommendation, with a mean target price of $40.0 based on one analyst opinion.
About Omeros Corporation
Omeros Corporation is a biotech firm based in Seattle, Washington. It focuses on discovering, developing, and commercializing treatments for immunologic diseases. Among its lead product candidates are Narsoplimab for treating stem-cell transplant-associated thrombotic microangiopathy and OMS527, which is in clinical trials for addiction and compulsive disorders. The company, led by CEO Dr. Gregory A. Demopulos, employs around 175 people.
Bottom Line
Insider buying activity at Omeros Corporation, including Peter Demopulos's recent purchase, signals confidence in the company's direction. Investors often track such moves for insights into management's outlook. However, it's important to remember that these trades are reported after the fact and may not reflect current positions.
Get Omeros Corporation alerts
New 13F filings, insider trades, and analyst moves on $OMER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.